The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
2 citations0 with PMIDValidation: 0%1 supporting / 1 opposing
✓For(1)
No supporting evidence
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
MECH 2CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Concrete next test: deliver BDNF-pathway activatio…
Supporting
MECH
AD-MASTER-PLAN-…
-
-
-
-
-
Promotion before replication would weaken quality …
Opposing
MECH
AD-MASTER-PLAN-…
-
-
-
-
-
Legacy Card View — expandable citation cards
✓ Supporting Evidence
1
Concrete next test: deliver BDNF-pathway activation in hippocampal circuit models and test synaptic function b…▼
Concrete next test: deliver BDNF-pathway activation in hippocampal circuit models and test synaptic function before tau-mediated degeneration
AD-MASTER-PLAN-BDNF-20260428030755
✗ Opposing Evidence
1
Promotion before replication would weaken quality control.
AD-MASTER-PLAN-BDNF-20260428030755
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-28 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theorist position for analysis AD-MASTER-PLAN-BDNF-20260428030755: AD Master Plan preregistration: BDNF
Context: Preregistered claim: BDNF-mediated hippocampal synaptic rescue restores CA3-CA1 connectivity and prevents downstream tau-mediated neurodegeneration in AD
Primary claim: BDNF-mediated hippocampal synaptic rescue as a modifier of CA3-CA1 vulnerability is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan preregistration, the debate shou
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic critique for analysis AD-MASTER-PLAN-BDNF-20260428030755: AD Master Plan preregistration: BDNF
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: neurotrophic rescue may improve plasticity markers without interrupting amyloid or tau-driven degeneration.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across BDNF, AD, tau
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain expert assessment for analysis AD-MASTER-PLAN-BDNF-20260428030755: AD Master Plan preregistration: BDNF
The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: deliver BDNF-pathway activation in hippocampal circuit models and test synaptic function before tau-mediated degeneration. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.
Feasibility is moderate beca
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "BDNF-mediated hippocampal synaptic rescue as a modifier of CA3-CA1 vulnerability requires proximal validation", "description": "The debate supports carrying forward BDNF-mediated hippocampal synaptic rescue as a modifier of CA3-CA1 vulnerability only if a proximal endpoint changes before the late outcome. The decisive validation path is: deliver BDNF-pathway activation in hippocampal circuit models and test synaptic function before tau-mediated degeneration.", "target_gene": "BDNF", "dimension_scores": { "evidence_stren
Price History
No price history recorded yet
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0
Clinical Trials (0)
No clinical trials data available
📚 Cited Papers (0)
No linked papers yet
📅 Citation Freshness Audit
Freshness score = exp(-age×ln2/5): halves every 5 years.
Green >0.6,
Amber 0.3–0.6,
Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.